Please check your internet connection and try again.
# Piperacillin-Tazobactam (Zosyn)
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of a penicillin-class drug (piperacillin) and a beta-lactamase inhibitor (tazobactam). It has broad-spectrum activity against many Gram-positive and Gram-negative bacteria, including *Pseudomonas aeruginosa*, and some anaerobic organisms.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
## Adult Dosing
* **Standard Dose:** 3.375 grams (3 g piperacillin/0.375 g tazobactam) or 4.5 grams (4 g piperacillin/0.5 g tazobactam) IV every 6 or 8 hours.
* **Severe or Naïve to Antibiotics:** Higher doses (e.g., 4.5 grams IV every 6 hours) may be preferred.
* **Duration of Therapy:** Typically 7-10 days, but depends on severity, pathogen, and clinical response.
## Pediatric Dosing
* **Patients 0 to < 2 months:** Dosing is highly variable and depends on gestational and chronological age, as well as renal function. Consult specific pediatric guidelines or institutional protocols.
* **Patients ≥ 2 months:**
* **General:** 90-100 mg piperacillin/11.25-12.5 mg tazobactam per kg per dose IV every 6 or 8 hours.
* **Maximum Dose:** Do not exceed the adult maximum of 4.5 grams per dose.
* **Note:** This dosing can be challenging to calculate for patients approaching adult weight.
## Dose Adjustments
* **Renal Impairment (CrCl < 20 mL/min):** Reduce dose frequency or dose. Consult prescribing information or institutional guidelines for specific adjustments. Dosing may need to be every 8-12 hours.
* **Hepatic Impairment:** No dose adjustment is generally recommended.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant penicillins, or other ingredients in the formulation.
* History of immediate and severe allergic reaction to a beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, pruritus, elevated liver enzymes (AST, ALT).
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (rare, especially with high doses or renal impairment), neutropenia, thrombocytopenia.
## Key Drug Interactions
* **Aminoglycosides:** Potential for antagonism; however, coadministration may be clinically indicated for certain infections (e.g., *Pseudomonas* infections). Monitor for efficacy and toxicity.
* **Probenecid:** May increase and prolong serum concentrations of piperacillin.
* **Neuromuscular blocking agents:** May prolong neuromuscular blockade.
* **Warfarin:** May decrease INR. Monitor INR closely.
## Monitoring
* **Renal function:** Especially in patients with pre-existing renal impairment or those receiving nephrotoxic agents.
* **Liver function tests:** Periodic monitoring may be considered, particularly with prolonged therapy.
* **Electrolytes:** Monitor for hypernatremia, especially with large doses and prolonged infusions.
* **Signs and symptoms of infection:** Clinical response.
* **Signs and symptoms of hypersensitivity reactions.**
* **Signs and symptoms of *C. difficile* infection.**
* **Complete blood count:** Monitor for neutropenia or thrombocytopenia with prolonged therapy.
## Clinical Pearls
* Piperacillin-tazobactam is often administered as a continuous infusion for critically ill patients or those with severe infections, which may improve efficacy and reduce toxicity. Dosing for continuous infusion is typically based on the 24-hour total dose. Consult institutional guidelines.
* Ensure adequate hydration to minimize risk of crystalluria.
* Reconstituted solutions should be used within 24 hours when refrigerated or within 12 hours at room temperature.
***
*Disclaimer: This information is intended for healthcare professionals and should be used as a reference. Always verify current prescribing information and consult with a pharmacist or physician before making clinical decisions. Dosing may vary based on institutional protocols, patient-specific factors, and the most current FDA-approved labeling.*
